Autologous, engineered T Cells targeting TP53 R175H therapy(Neogene Therapeutics)

N/A

Report date: 2024/08/07 20:00:43

Base Information

Drug NameAutologous, engineered T Cells targeting TP53 R175H therapy(Neogene Therapeutics)
Drug Alias Nameautologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR)NT-175
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsTumor protein p53 modulators
TargetsTumor protein p53
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeogene Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A